US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(OP:
BNXTF
)
0.2700
UNCHANGED
Delayed Quote
Updated: 1:55 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BNXTF
< Previous
1
2
3
Next >
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
September 08, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
August 19, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 17, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
August 04, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
July 06, 2026
From
BioNxt Solutions Inc.
Via
ACCESS Newswire
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
June 15, 2026
Via
ACCESS Newswire
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
May 19, 2026
Via
ACCESS Newswire
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
April 28, 2026
Via
ACCESS Newswire
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
April 14, 2026
Via
ACCESS Newswire
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
April 07, 2026
Via
ACCESS Newswire
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
March 30, 2026
Via
ACCESS Newswire
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
March 24, 2026
Via
ACCESS Newswire
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
March 17, 2026
Via
ACCESS Newswire
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
February 17, 2026
Via
ACCESS Newswire
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
February 05, 2026
Via
ACCESS Newswire
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
January 21, 2026
Via
ACCESS Newswire
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
January 19, 2026
Via
ACCESS Newswire
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
December 17, 2025
Via
ACCESS Newswire
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
December 09, 2025
Via
ACCESS Newswire
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
December 01, 2025
Via
ACCESS Newswire
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
November 20, 2025
Via
ACCESS Newswire
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
November 04, 2025
VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF...
Via
PressReach
Topics
Intellectual Property
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
November 04, 2025
Via
ACCESS Newswire
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
October 30, 2025
VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased...
Via
PressReach
Topics
Intellectual Property
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
October 30, 2025
Via
ACCESS Newswire
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
October 22, 2025
BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead...
Via
PressReach
Topics
Intellectual Property
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
October 21, 2025
VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,...
Via
PressReach
Topics
Intellectual Property
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
October 21, 2025
Via
ACCESS Newswire
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
October 09, 2025
Via
ACCESS Newswire
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
October 02, 2025
Via
ACCESS Newswire
< Previous
1
2
3
Next >
